Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Boston Technology Review.
Press releases published on September 8, 2025
Genius Group appoints Saifedean Ammous as Board Advisor
GlobeNewswire
·
September 8, 2025
SINGAPORE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered, Bitcoin-first education group, today announced that it has appointed Saifedean Ammous as an advisor to the …
Rezolve Ai CEO Engages Wall Street with Packed September Investor Line-Up
GlobeNewswire
·
September 8, 2025
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rezolve Ai (NASDAQ: RZLV), a leader in proprietary AI-powered commerce solutions, today announced that CEO Daniel M. Wagner will present at the HC Wainwright Global Tech Investor Conference this week, …
ModelOp Announces 2025 AI Governance Leadership Summit on October 15 - The Agentic Advantage: How Enterprises Innovate Without Losing Control
GlobeNewswire
·
September 8, 2025
CHICAGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Agentic AI is unlike anything large enterprises have introduced or scaled before and preparing for it requires a fundamental shift - including new architecture, control models, and an operating culture. ModelOp, …
SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds
GlobeNewswire
·
September 8, 2025
SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced the entry into …
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
GlobeNewswire
·
September 8, 2025
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative …
ElevateBio Appoints Larry Lockwood, Ph.D., as Chief Commercial Officer
GlobeNewswire
·
September 8, 2025
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, announced the appointment of Larry Lockwood, Ph.D., as Chief Commercial Officer. Dr. …
Humanoid Global Announces Strategic Investment in RideScan, a Pioneer Advancing AI for Robotics Safety and Performance
GlobeNewswire
·
September 8, 2025
Vancouver, BC …
Xtract One Selected by Delmar School District for Enhanced Security Solutions
GlobeNewswire
·
September 8, 2025
TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”) today announced its Xtract One Gateway (“Gateway”) system has been selected by Delmar School District in Delmar, …
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
GlobeNewswire
·
September 8, 2025
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the company’s anti-CD20 monoclonal antibody, in people …
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025
GlobeNewswire
·
September 8, 2025
• Clinical data demonstrated administration of AGA2115 drove dose-dependent increases in bone mineral density • The Company and collaborators also presented data from non-human primate and mouse models WESTLAKE VILLAGE, Calif., Sept. 08, 2025 (GLOBE …
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database
GlobeNewswire
·
September 8, 2025
5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partners New hospital-based data seeks to further differentiate pending kitted assay that measures biomarker for transplanted organ rejection (dd-cfDNA) Novel …
Bitcoin Bancorp (OTC: BULT) Retained by NASDAQ-Listed Sadot Group (NASDAQ: SDOT) to Develop Institutional Bitcoin Treasury Strategy
GlobeNewswire
·
September 8, 2025
LAS VEGAS, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Bitcoin Bancorp. (OTC: BULT) (“Bitcoin Bancorp” or the “Company”), formerly Bullet Blockchain, Inc., a leading advisor in Bitcoin treasury strategies and institutional digital asset management, today announced …
Kraig Biocraft Laboratories Appoints Kenneth Le as Managing Director of Prodigy Silk
GlobeNewswire
·
September 8, 2025
ANN ARBOR, Mich., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, is happy to announce the appointment of Mr. Kenneth Le as Managing Director of its …
Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
GlobeNewswire
·
September 8, 2025
-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the …
Wix Announces Proposed Private Offering of $750 million of 0.00% Convertible Senior Notes due 2030
GlobeNewswire
·
September 8, 2025
NEW YORK, September 8, 2025 – Wix.com Ltd. (Nasdaq: WIX) (“Wix”), the leading SaaS website builder platform1, today announced its intention to offer, subject to market conditions and other factors, $750 million aggregate principal amount of 0.00% …
Attralus Presents New Data on Its Pan-Amyloid Diagnostic Imaging Candidates at ASNC 2025
GlobeNewswire
·
September 8, 2025
124I-evuzamitide, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected of or diagnosed with cardiac amyloidosis in ATTR, AL, and other rare types of …
Vertex to Present at Goldman Sachs Communacopia + Technology Conference
GlobeNewswire
·
September 8, 2025
KING OF PRUSSIA, Pa., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a global provider of tax technology solutions, today announced that David DeStefano, Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in …
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants
GlobeNewswire
·
September 8, 2025
iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previously GraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight …
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
GlobeNewswire
·
September 8, 2025
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in over 15 years Two pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared …
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
GlobeNewswire
·
September 8, 2025
Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13 Claseprubart …